In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
The in vitro activities of three new triazoles were determined and compared to those of itraconazole and fluconazole against 306 clinical isolates of Blastomyces dermatitidis, Cladophialophora carrionii, Coccidioides immitis, Fonsecaea pedrosoi, Fusarium spp., Histoplasma capsulatum, Paecilomyces lilacinus, Pseudallescheria boydii and Sporothrix schenckii. Minimum inhibitory concentrations (MIC) were determined by a broth macrodilution method of the National Committee for Clinical Laboratory Standards M38-A procedure. Itraconazole (geometric mean MIC, 0.16-0.65 microg/ml), voriconazole (geometric mean MIC, 0.18-1.44 microg/ml), ravuconazole (geometric mean MIC, 0.18-1.09 microg/ml), and posaconazole (geometric mean MIC, 0.18-1.38 microg/ml), had relatively uniform values showing potent in vitro inhibitory activity against B. dermatitidis, C. carrionii, C. immitis, F. pedrosoi, H. capsulatum, and S. schenckii. The in vitro activity was variable with strains of P. boydii, P. lilacinus and Fusarium spp.
González
Gloria M
GM
Departamento de Microbiología, Facultad de Medicina, Universidad Autónoma de Nuevo Léon, Monterrey, Nuevo Léon, México. gmglez@yahoo.com.mx
Fothergill
Annette W
AW
Sutton
Deanna A
DA
Rinaldi
Michael G
MG
Loebenberg
David
D
D000935:Antifungal Agents / Q000494:pharmacology; D005658:Fungi / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000382:microbiology; D011743:Pyrimidines / Q000494:pharmacology; D013045:Species Specificity; D013844:Thiazoles / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D013844:Thiazoles; D014230:Triazoles; C101425:posaconazole; C104066:ER 30346; D065819:Voriconazole